NPCE
Neuropace Inc
14.70$
+1.2%
vs. previous close
Closing price · As of: Sep 22, 2026
Statements
Income Statement
All figures as a percentage of revenue in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| 25.5% | 24.8% | 26.4% | 26.6% | 26.8% | 24.6% | 23.0% | 22.9% | 22.6% | 22.6% | 18.2% | 17.2% | 20.4% | |
| 74.5% | 75.2% | 73.6% | 73.4% | 73.2% | 75.4% | 77.0% | 77.1% | 77.4% | 77.4% | 81.8% | 82.8% | 79.6% | |
| 29.2% | 29.9% | 31.9% | 31.5% | 27.3% | 28.2% | 33.0% | 29.1% | 24.0% | 26.4% | 32.6% | 30.2% | 28.0% | |
| 81.5% | 73.4% | 83.3% | 23.6% | 66.0% | 64.2% | 18.0% | 25.8% | 16.8% | 16.5% | 22.0% | 22.0% | 19.1% | |
| 110.7% | 103.2% | 115.3% | 105.8% | 93.4% | 92.4% | 99.8% | 106.1% | 86.9% | 84.0% | 107.0% | 105.4% | 94.9% | |
| -36.2% | -28.0% | -41.6% | -32.4% | -20.1% | -17.0% | -22.9% | -29.0% | -9.5% | -6.6% | -25.2% | -22.5% | -15.3% | |
| 13.3% | 12.4% | 12.5% | 11.2% | 10.4% | 10.2% | 9.6% | 8.8% | 6.0% | 6.0% | 6.9% | 6.7% | 6.4% | |
| -44.2% | -34.4% | -49.2% | -39.0% | -25.9% | -24.5% | -29.3% | -36.8% | -12.8% | -10.3% | -30.3% | -27.2% | -19.3% | |
| 14.0% | -47.6% | 2.1% | – | – | -1.8% | – | – | – | -32.5% | – | – | – | |
| -44.2% | -34.4% | -49.2% | -39.0% | -25.9% | -24.5% | -29.3% | -36.8% | -12.8% | -10.3% | -30.3% | -27.2% | -19.3% | |
| -28.4% | -19.7% | -34.5% | -25.5% | -13.4% | -12.1% | -17.6% | -26.0% | -9.0% | -2.3% | -21.1% | -20.0% | -12.4% |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: September 22, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.